**Supplemental data:**

**Supplemental figure 1:** **Immunohistological stainings of breast tumors for EZH2.** Shown are representative examples of low (<50%) and high (>50%) abundance, respectively. (a) Set I (Cologne Cohort: antibody against EZH2/Ezh2 (1:100, BD Biosciences). (b) Set IV (N4+): antibody against EZH2/Ezh2 (1:800, Leica, NCL-L-EZH2).

**Supplemental figure 2: Predictive value of EZH2-expression in non-*BRCA1-*like breast cancer patients treated with conventional (CONV) or high dose (HD) platinum-based chemotherapy (Set IV N4+, HER2-negative) divided by ER status.**(a) Kaplan-Meier curves of disease free survival (DFS) of non-*BRCA1*-like patients with high EZH2-expression for ER+ (n=53) and ER- (n=18) cases (b) Kaplan-Meier curves of overall survival (OS) of non-*BRCA1*-like patients with high EZH2-expression for ER+ (n=53) and ER- (n=18) cases. Log-rank test were applied and *P*<0.05 was considered statistically significant.